GDTC Stock Performance, Insider Transaction and News

GDTC - CytoMed Therapeutics Limited

Market Cap	49.81M	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-4.13M	Forward P/E	-17.28	EPS next Y	-	50D Avg Chg	29.00%
Sales	507.74k	PEG	-	EPS past 5Y	-	200D Avg Chg	29.00%
Dividend	N/A	Price/Book	61.71	EPS next 5Y	-	52W High Chg	-53.00%
Recommedations	2.00	Quick Ratio	12.83	Shares Outstanding	11.54M	52W Low Chg	83.00%
Insider Own	69.27%	ROA	-27.30%	Shares Float	3.55M	Beta	-
Inst Own	0.04%	ROE	-69.87%	Shares Shorted/Prior	122.65K/119.31K	Price	4.32
Gross Margin	99.27%	Profit Margin	-	Avg. Volume	501,425	Target Price	-
Oper. Margin	-811.27%	Earnings Date	-	Volume	59,734	Change	3.35%

Healthcare | Biotechnology | Singapore

About CytoMed Therapeutics Limited

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

CytoMed Therapeutics Limited News

11/20/24	Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
10/23/24	Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
10/07/24	CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
10/04/24	CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine
10/03/24	CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
09/30/24	CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
09/25/24	Presenting on the Emerging Growth Conference 75 Day 2 on September 26
08/20/24	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
07/17/24	CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
07/17/24	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
03/20/24	CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
03/18/24	CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
03/04/24	CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
01/29/24	Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
10:44 AM	One CytoMed Therapeutics Insider Raised Stake By 46% In Previous Year
12/05/23	CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

GDTC Chatroom

ZachariahBall Posted - 1 day ago

$GDTC $NN LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

AlphaTuna Posted - 1 week ago

Lowest Volume Rated General Stocks Per 11/12/2024’s Close: 1 – $LIANY 2 – $CRSFX 3 – $CNND 4 – $OIIIF 5 – $GDTC 6 – $BNPQF 7 – $WEGYF 8 – $STEC 9 – $MRM 10 – $INBP https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-11-12-2024/

DamonStep Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $GDTC $NN $BTTR $TLS

CedricBenton_ Posted - 10/28/24

$GDTC $MNPR $NWTN $UPXI $JFBR

LeeVaughan_ Posted - 10/28/24

$GDTC $MNPR $NWTN $UPXI $JFBR

Ric_1M Posted - 10/28/24

$GDTC $NWTN $UPXI $MNPR $JFBR “Never confuse your position with your best interest. Many traders take a position in a stock and form an emotional attachment to it. They'll start losing money, and instead of stopping themselves out, they’ll find brand new reasons to stay in. When in doubt, get out!” Jeff Cooper

_www_larval_com_ Posted - 10/23/24

$GDTC has reverted -7% lower to 15% (~123Kv) moments ago, follow for more volatility.

VrtcIl Posted - 10/23/24

$GDTC still gaining momentum towards 4$. The long trend is supported by consistent increased highs and increased lows, with notable volume signaling increased buying interest. Price: 3.5 Float: 4.1M Short Float: 2.5 % 💰 Dollar Volume: 3.1K ℹ️ Singapore | Biotechnology

builderup Posted - 1 month ago

Research, Buy, Hold and Bank!!!! $ENGN =BANK $GDTC =bank $VRPX =bank $ADIL =up next? $CTXR averaged down. Patiently waiting.

BPharmCatalyst Posted - 1 month ago

$SRRK announced topline results from its Phase 3 SAPPHIRE clinical trial evaluating apitegromab for treating spinal muscular atrophy (SMA). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor function, as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE). See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2024/scholar-srrk-phase-3-data-trevena-trvn-stock-to-delist $TRVN $GDTC $DWTX $ONCO

themacromindset Posted - 1 month ago

$GDCT $GDTC CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank